Order Article Reprints

Rupp M, Fanton-Aita F, Snow S, Wheatley-Price P, Melosky B, Juergens RA, Chu Q, Blais N, Banerji S, Ng R, et al. Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. Current Oncology. 2023; 30(7):6559-6574. https://doi.org/10.3390/curroncol30070481

Rupp, Martin, Fiorella Fanton-Aita, Stephanie Snow, Paul Wheatley-Price, Barbara Melosky, Rosalyn A. Juergens, Quincy Chu, Normand Blais, Shantanu Banerji, Ryan Ng, and et al. 2023. "Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience" Current Oncology 30, no. 7: 6559-6574. https://doi.org/10.3390/curroncol30070481

Rupp, M., Fanton-Aita, F., Snow, S., Wheatley-Price, P., Melosky, B., Juergens, R. A., Chu, Q., Blais, N., Banerji, S., Ng, R., Khoudigian, S., Sharma, A., On, P. V., & Liu, G. (2023). Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. Current Oncology, 30(7), 6559-6574. https://doi.org/10.3390/curroncol30070481